The company s legal predecessor was founded in 1913. Its main activity is the development, manufacture and distribution of primarily generic drugs and their active ingredients. More than 70 per cent of Egis revenues originate from export sales, with its products being exported to the CIS markets and Eastern European countries, to a marketplace where the company has established strong positions through its effective marketing presence. Since the first half of the 1990s, the company has also exported pharmaceuticals to a growing number of Western, predominantly West European countries. In December 1995, the French partner Servier SAS acquired 50.9 percent of the company shares, and a strong strategic alliance has been developed between the two pharma companies ever since. This has also been a major factor contributing to Egis appearance on the French market.
Note: When determining the Free Float for a particular series, all the securities of the company shall be regarded to be publicly held other than (i) the stock of securities held by holders with direct holdings of at least 5% of the total number of securities, (ii) securities in the possession of custodians, provided the certificate available to the custodian verifies that the particular person holds at least 5% of the total number of securities outstanding.
Dr. Jean-Philippe SETA chairman, Nicolas BOUTS, Christian BAZANTAY, FEHÉRDI Zsolt, GÁL Péterné, Dr. HODÁSZ István, Yves LANGOURIEUX, Olivier LAUREAU, POROSZLAI Csaba, Dr. VERESS József, Christian SAUVEUR
Dr. HODÁSZ István CEO, POROSZLAI Csaba CFO, FEHÉRDI Zsolt technical director, Dr. SZENTPÉTERI Imre director of R&D, dr. MÁZSÁR Péter director of comm., dr. SZEMERÉDI Katalin director of HR
KOVÁCS Andor chairman, dr. BÁLINT Konrádné, NAGY Imre, Georges RADVANYI, dr. RESZEGI László, FELSMANNÉ BÖLÖNI Eszter, GASZTONY Balázs, Dr. NAGY Gábor István